BOSTON – Veloxis Pharmaceuticals, Inc. (Veloxis), a drug manufacturer based in Cary, N.C., has agreed to pay over $46 million to resolve criminal and civil allegations that it paid kickbacks to induce prescriptions and purchases of Envarsus XR (Envarsus), the company’s kidney transplant immunosuppression drug.
Source: U.S. Department of Justice